About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.


The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

Aniling Women

International Women’s Day 2023

Today we are proud to celebrate and recognize the remarkable contributions of women and girls everywhere. Many women are still facing significant barriers due to gender bias and we believe …


Open Position: Bioinformatician [Aniling202301]

Aniling is hiring a bioinformatician to join our team! Interested applicants should send the following documents to info@aniling.com: – A short statement of motivation – A CV including your contact …